Wuxi to Help Develop, Manufacture ADC Candidate in China

Wuxi to Help Develop, Manufacture ADC Candidate in China

Ambrx and Zhejiang Medicine have selected Wuxi to accelerate the development of a potential ADC (antibody drug conjugate) targeting Her2-positive breast cancer.

In this deal, WuXi will provide contract services to Ambrx and Zhejiang from process development, manufacturing clinical drug including conjugating antibody with toxin, preclinical studies and potentially perform clinical trials in China,” Wuxi spokesman Aaron Shi told us.

San Diego-based biopharma company Ambrx sought the partnership with Zhejiang and Wuxi to gain access to the Chinese market for ARX788, which is the company’s most advanced ADC for breast and gastric cancer indications.

Zhejiang will bear the development costs and will gain commercial rights in China, while Ambrx keeps its commercial rights outside of China and will receive royalties on sales of the ADC in China.

Ambrx and Zhejiang will “leverage WuXi's capabilities to bring innovative antibody-ADC drug to China much faster than they can do by themselves,” Shi said.

The partnership shows further progress the company is making in the development of biologics, which it said would be expected in comments from its latest earnings call.

Wuxi is the only company in China to have this integrated biologics drug discovery, development and manufacturing capabilities that meet global quality standard,” Shi added.

Last October, the company opened a biologics manufacturing facility in Wuxi, China, and which the company claims is the country’s first site to comply with US and EU GMP (good manufacturing practice) standards.

Related News

WuxiPRA JV Nabs Ex-Theorem CEO as President

WuxiPRA JV Nabs Ex-Theorem CEO as President

Wuxi Buys Remote  Monitoring Tech

Wuxi Buys Instem’s Remote Study Monitoring Tool

Pharma returning West for biomanufacturing partners

BioPharmas That Favour Western CMOs May Soon Look to Asia say Experts

Wuxi’s Q2 Revenue Jumps as China Lab Services Drive Growth

Wuxi’s Q2 Revenue Jumps as China Lab Services Drive Growth

Chinese drugmakers increasingly look to Western markets, says Diapharm

Chinese drugmakers eyeing West must up quality, says Diapharm

Competition not a concern says Carbogen Amcis CEO

Carbogen Amcis CEO: Competition in ADC sector not a concern

Another day, another ADC investment: SAFC adds ADC capacity

Another day, another ADC investment: SAFC adds commercial-scale capacity

ADCs a big opportunity for Big Pharma say experts

Big Pharma business opportunities driving ADC boom say experts

US FDA gives green light for WuXi intermediate manufacturing

US FDA gives green light for WuXi intermediate manufacturing

ADCT and Prime are working together to develop ADCs

ADC Therapeutics licenses proprietary antibodies from Five Prime

Wuxi expects biologics CMO biz to grow in 2014

Wuxi slightly raises financial expectations for 2013

Wuxi predicts biomanufacturing upswing in 2014

Wuxi predicts growth for biologics manufacturing in 2014

WuXi reveals steep increase in quarterly manufacturing revenues

WuXi reveals steep increase in quarterly manufacturing revenues

Talking ADCs with SAFC, Piramal and Catalent at CPhI Frankfurt

'The sexiness of the ADC world' - CMOs talk antibody-drug hybrids at CPhI

Wuxi to build new cell therapy manufacturing facility in Pennsylvania

Wuxi to equip new cell therapy plant with single-use systems

ADC conjugation tech firm Ambrx looks to raise $86m in IPO

ADC conjugation tech firm Ambrx looks to raise $86m in IPO

"Solid technical expertise and extreme level of quality" holding back Chinese biologics manufacturing, says WuXi

'Milestone for Chinese Biologics' as WuXi wins mAb contract

WuXi expands in US with acquisition of CRO XenoBiotic Laboratories

WuXi expands testing division in US with acquisition of CRO XenoBiotic Laboratories

WuXi reports increase in biomanufacturing demand

WuXi plans commercial biomanufacturing plant on back of biologics demand

WuXi, Fudan University forge partnership around human genomics

WuXi, Fudan University forge partnership around human genomics

WuXi to create $200m investment fund following initial success

WuXi to create $200m investment fund following initial success

WuXi inks CV development and manufacture deal with Eli Lilly in China

WuXi inks CV development and manufacture deal with Eli Lilly in China

WuXi buys two Chinese CROs in clinical trial expansion

Wuxi Manufacturing Services Help Increase Quarterly Earnings

Wuxi Manufacturing Services Help Increase Quarterly Earnings

WuXi Expands Antibody Discovery with Transgenic Animal Developer

WuXi Expands Antibody Discovery Partnership with Transgenic Animal Developer

Related Products

See more related products